The role of genotype and diet in shaping gut microbiome in a genetic Vitamin A deficient mouse model

The role of genotype and diet in shaping gut microbiome in a genetic Vitamin A deficient mouse model

Multi-factors have been reported to have an effect on the intestine microbiome, together with genotype, age, eating regimen, and diet. Nevertheless, few experiences have investigated the relative capability of various elements to form the intestine microbiome in a single research.
Our design used a genetic Vitamin A poor mouse mannequin, the Rbp4-/- mouse, feeding with the low Vitamin A diets at totally different ages of initiation (four or 7 weeks) for 28 days. Fecal samples had been collected for bacterial profiling at seven time factors after eating regimen controlling.
With RBP4 depletion, Akkermansia decreased and Bacteroides elevated, whereas Desulfovibrio, Barnesiella, Clostridium_XlVa, and Lactobacillus fluctuated. The bacterial group swiftly adjusted with the Vitamin A-deficient eating regimen administration and step by step modified (e.g., lower of Barnesiella and improve of Desulfovibrio).
Age exerted a comparatively weaker however long-last affect. At an earlier age to feed a Vitamin-A poor eating regimen, a better microbial dysbiosis index (MDI) will probably be valued. Of notice, the shaping results of eating regimen and age on the bacterial group various with the distinction of genotype, which could point out a better function of genotype than eating regimen and age in shaping the intestine microbiome.

Two Kinds of Mouse Fashions for Sarcopenia Analysis: Senescence Acceleration and Genetic Modification Fashions

Sarcopenia results in lack of skeletal muscle mass, high quality, and energy as a consequence of growing old; it was lately given a illness code (Worldwide Classification of Illnesses, Tenth Revision, Medical Modification, M62.84). Consequently, lately, sarcopenia-related analysis has elevated.
As well as, numerous research in search of to forestall and deal with sarcopenia by figuring out the varied mechanisms associated to the discount of skeletal muscle properties have been carried out. Earlier research have recognized muscle synthesis and breakdown; investigating them has generated proof for stopping and treating sarcopenia.
Mouse fashions are nonetheless essentially the most helpful ones for figuring out mechanisms underlying sarcopenia by correlations and interventions involving particular genes and their phenotypes. Mouse fashions used to check sarcopenia typically induce muscle atrophy by hindlimb unloading, denervation, or immobilization.
Although it’s much less regularly used, the senescence-accelerated mouse may also be helpful for sarcopenia analysis. Herein, we focus on instances the place senescence-accelerated and genetically engineered mouse fashions had been utilized in sarcopenia analysis and totally different views to make use of them.

CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Mannequin of Hemophilia A

Hemophilia A (HA), a standard bleeding dysfunction attributable to a deficiency of coagulation issue VIII (FVIII), has lengthy been thought-about a beautiful goal for gene remedy research. Nevertheless, full-length F8 cDNA can’t be packaged effectively by adeno-associated virus (AAV) vectors.
Because the second most prevalent mutation inflicting extreme HA, F8 intron 1 inversion (Inv1) is attributable to an intrachromosomal recombination, leaving the vast majority of F8 (exons 2-26) untranscribed. In concept, the truncated gene could possibly be rescued by integrating a promoter and the coding sequence of exon 1. To check this technique in vivo, we generated an HA mouse mannequin by deleting the promoter area and exon 1 of F8.
Donor DNA and CRISPR/SaCas9 had been packaged into AAV vectors and injected into HA mice intravenously. After remedy, F8 expression was restored and activated partial thromboplastin time (aPTT) was shortened. We additionally in contrast two liver-specific promoters and two forms of integrating donor vectors.
When an lively promoter was used, all the handled mice survived the tail-clip problem. That is the primary report of an in vivo gene restore technique with the potential to deal with a recurrent mutation in HA sufferers.

Carrot Supplementation Improves Blood Stress and Reduces Aortic Root Lesions in an Atherosclerosis-Susceptible Genetic Mouse Mannequin

Epidemiological research have proven that carrot consumption could also be related to a decrease threat of growing a number of metabolic dysfunctions. Our group beforehand decided that the Bolero (Bo) carrot selection exhibited vascular and hepatic tropism utilizing mobile fashions of cardiometabolic ailments.
The current research evaluated the potential metabolic and cardiovascular protecting impact of Bo, grown underneath two circumstances (commonplace and biotic stress circumstances (BoBS)), in apolipoprotein E-knockout (ApoE-/-) mice fed with excessive fats eating regimen (HFD).
Results on metabolic/hemodynamic parameters and on atherosclerotic lesions have been assessed. Each Bo and BoBS decreased plasma triglyceride and expression ranges of genes implicated in hepatic de novo lipogenesis and lipid oxidation. BoBS supplementation decreased physique weight achieve, secretion of very-low-density lipoprotein, and elevated cecal propionate content material.
Curiously, Bo and BoBS supplementation improved hemodynamic parameters by lowering systolic, diastolic, and imply blood strain. Furthermore, Bo improved cardiac output. Lastly, Bo and BoBS considerably diminished the aortic root lesion space.
These outcomes confirmed that Bo and BoBS enriched diets corrected a lot of the metabolic and cardiovascular issues in an atherosclerosis-prone genetic mouse mannequin and will subsequently signify an fascinating dietary method for the prevention of cardiovascular ailments.
 The role of genotype and diet in shaping gut microbiome in a genetic Vitamin A deficient mouse model

Integration of Molecular Evaluation, Slicing-edge Mouse Genetic Fashions and Proton Remedy to Enhance Outcomes for Glioma Sufferers

Regardless of current advances on the whole most cancers remedy, glioblastoma stays among the many most deadly of human malignancies. Even with aggressive multimodal radiation and chemotherapy after surgical procedure, glioblastoma recurs with a bleak prognosis.
Many years of analysis centered on methods corresponding to rising radiation sensitivity and interference with oncogenic sign transduction have yielded solely incremental enhancements at finest. That is due partially to the radioresistance of glioblastoma and molecular heterogeneity of tumor cells.
We hypothesize is that the event of simpler glioblastoma therapies would require: (i) a extra correct molecular evaluation of glioblastoma in order to foretell response to remedy; (ii) higher genetically engineered mouse fashions, which may faithfully recapitulate human glioblastoma and the tumor microenvironment to check new approaches and (iii) growth and utility of extra correct and centered strategies to ship sustained excessive vitality particles to glioblastoma tumor websites.
This chapter describes the present state-of-the-art molecular evaluation approaches, newest in glioma mouse modelling, and advances within the utility of proton remedy remedy and analysis. By integrating primary and scientific analysis with cutting-edge applied sciences, a mechanistic understanding of glioblastoma remedy resistance and pathogenesis and the event of recent therapeutics to beat the therapeutic resistance of glioblastoma will probably be superior.

Altered neural oscillations and habits in a genetic mouse mannequin of NMDA receptor hypofunction

Abnormalities in electroencephalographic (EEG) biomarkers happen in sufferers with schizophrenia and people clinically at excessive threat for transition to psychosis and are related to cognitive impairment. Converging proof suggests N-methyl-D-aspartate receptor (NMDAR) hypofunction performs a central function within the pathophysiology of schizophrenia and sure contributes to biomarker impairments.
Thus, characterizing these biomarkers is of great curiosity for early analysis of schizophrenia and growth of novel remedies. We utilized in vivo EEG recordings and behavioral analyses to carry out a battery of electrophysiological biomarkers in a longtime mannequin of persistent NMDAR hypofunction, serine racemase knockout (SRKO) mice, and their wild-type littermates.
SRKO mice displayed impairments in investigation-elicited gamma energy that corresponded with diminished short-term social recognition and enhanced background (pre-investigation) gamma exercise. Moreover, SRKO mice exhibited sensory gating impairments in each evoked-gamma energy and event-related potential amplitude.
Nevertheless, different biomarkers together with the auditory steady-state response, sleep spindles, and state-specific energy spectral density had been typically neurotypical. In conclusion, SRKO mice display how persistent NMDAR hypofunction contributes to deficits in sure translationally-relevant EEG biomarkers altered in schizophrenia.

Mouse PlGF-2 ELISA Kit

E16ME0045 96T
EUR 833.33

Rat Monoclonal anti-mouse PlGF

mAP-0010 100ug
EUR 250

PLGF (PGF) (PlGF-1/2) mouse monoclonal antibody, clone 178/G10, Biotin, Purified

DM3525B 50 µg Ask for price

Mouse PlGF Recombinant Protein

M30-019 5 µg
EUR 136.5
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Mouse PlGF Recombinant Protein

M30-019S 2 µg
EUR 73.5
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF-1, PlGF-2 and PlGF-3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF-2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF-2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Mouse PlGF Recombinant Protein

M30-020 20 µg
EUR 313.95
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

PLGF (Mouse, monoclonal, antagonistic)

mP1002r-m 100ug
EUR 467.5

Mouse PLGF-2 PicoKine ELISA Kit

EK0863 96 wells
EUR 510
Description: For Quantitative Detection of mouse PLGF-2 in cell culture supernates, serum and plasma (heparin, EDTA).

Anti-Rat PlGF Antibody

104-PA04AG 50 µg
EUR 157.5
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Anti-Rat PlGF Antibody

104-PA04S 100 µg
EUR 126
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In rat only one PlGF that is the equivalent of human PlGF-2 has been identified. Rat PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, mouse, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic PlGF antibodies are being investigated to inhibit tumor growth and angiogenesis.

PLGF (PGF) mouse monoclonal antibody, clone PLGF94, Purified

AM50307PU-S 100 µg Ask for price

PLGF (PGF) mouse monoclonal antibody, clone PLGF94, Purified

AM50307PU-T 20 µg Ask for price

Rabbit anti PlGF (human)

102-PA04AG 50ug
EUR 240

Rabbit anti PlGF (human)

102-PA04S 100ug
EUR 240

Rabbit Anti-Rat PlGF

104-PA04 100ug
EUR 240

Anti-Human PlGF Antibody

102-P248 100 µg
EUR 245.7
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-MBi67 50 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-M03 100 µg
EUR 378
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-M67 100 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-M69 100 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF-2 Antibody

101-M65 100 µg
EUR 246.75
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF-2 Antibody

101-M65A 100 µg
EUR 246.75
Description: Placenta Growth Factor-2 (PlGF-2), a 22 kDa protein consisting of 152 amino acid residues is produced as a homodimer. PlGF is a polypeptide growth factor and a member of the platelet-derived growth factor family but more related to vascular endothelial growth factor (VEGF). PlGF acts only as a weak mitogen for those cell types possessing receptors for binding (e.g. vascular endothelial cells). At least one high-affinity receptor for PlGF (FLT-1 or VEGF-R1) has been demonstrated in different primary cell types (e.g. human umbilical vein endothelial cells and monocytes). In addition to its action as a weak mitogen it is also a chemoattractant for monocytes and endothelial cells. Three different proteins are generated by differential splicing of the human PlGF gene: PlGF-1 (131aa native chain), PlGF-2 (152aa) and PlGF-3 (203aa). All 3 mitogens are secretable proteins, but PlGF-2 can bind to heparin with high affinity. PlGF is apparently a homodimer, but preparations of PlGF show some heterogeneity on SDS gels depending of the varying degrees of glycosylation. All dimeric forms possess similar biological activities. Heterodimers between VEGF and PlGF are mitogenic for endothelial cells and have strong angiogenic activity in vivo (e.g. in the CAM assay or in the cornea pocket assay). Different cells and tissues (e.g. placenta) express PlGF-1 and PlGF-2 at different rates. A much related protein of PlGF is VEGF with about 53% homology and VEGF-B with similar biological activities.

Mouse PLGF / PGF Protein, His Tag

PGF-M52H0 50ug
EUR 3327.7
Description: Mouse PLGF, His Tag (PGF-M52H0) is expressed from human 293 cells (HEK293). It contains AA Val 19 - Pro 158 (Accession # P49764-1).

PLGF(PLGF93) Antibody

BNCH0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCH0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCA0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCA0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCP0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCP0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCR0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), RPE conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCR0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), RPE conjugate, Concentration: 0.1mg/mL

OKRC01283-96W - PLGF-2 ELISA Kit (Mouse)

OKRC01283-96W 96Wells
EUR 525

Anti-Human PlGF (native) Antibody

102-PABi04 50 µg
EUR 157.5
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

PLGF

E8EM1701-88 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

E8EM1701-90 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

E8ER1706-88 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

E8ET1704-99 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

PA1066 100μg
EUR 260

PLGF

PA1066-M 100μg
EUR 290
Description: Polyclonal Antibodies Conjugated to Magnetic Beads

PLGF

PA1066-S 100μg
EUR 290
Description: Polyclonal Antibodies Conjugated to Sepharose Beads

Anti-Human PlGF (Peptide) Antibody

102-PA01S 100 µg
EUR 115.5
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Rabbit Anti-Human PlGF (native)

102-PA04 100ug
EUR 240

Polyclonal Anti-PGF (PLGF) Antibody

GWB-BBP088 0.1 mg Ask for price

Rabbit Anti-Human PlGF (Peptide)

102-PA01 100ug
EUR 240

PLGF Antibody

E8RT1505 100ul
EUR 225
Description: Available in various conjugation types.

PLGF Antibody

49602 100ul
EUR 499

PLGF Antibody

49602-100ul 100ul
EUR 399.6

PLGF Antibody

49602-50ul 50ul
EUR 286.8

PlGF antibody

70R-12427 100 ug
EUR 371
Description: Rabbit polyclonal PlGF antibody

PlGF Antibody

5743-100 each
EUR 405.6

PlGF Antibody

5743-30T each
EUR 175.2

PLGF Antibody

GWB-628116 0.1 mg Ask for price

PLGF Antibody

R30247 100 ug
EUR 356.15
Description: Placental growth factor(PGF, also known as PLGF) codes for an angiogenic factor expressed in placental tissue that is similar to vascular permeability factor/vascular endothelial growth factor(VPF/VEGF). It is a glycosylated dimeric secreted protein able to stimulate endothelial cell growth in vitro. PGF is located on chromosome 14 and has been conserved in evolution. It belongs to the family of vascular endothelial growth factors(VEGFs) and binds to the flt-1 VEGF receptor. PLGF-2, which is a PLGF isoform, binds neuropilin-1 and 2 in a heparin-dependent manner. PGF regulates inter- and intra molecular cross talk between the VEGF RTKs Flt1 and Flk1 and stimulates the phosphorylation of specific Flt1 tyrosine residues and the expression of distinct downstream target genes. Moreover, it plays an important role in pathological angiogenic events and with exerting its biological activities through binding to VEGFR1.

PLGF Antibody

R34945-100UG 100 ug
EUR 339.15
Description: Additional name(s) for this target protein: Placental growth factor; PGF

Sheep Polyclonal anti-human PlGF

hAP-5406 50ug
EUR 400

PlGF-1 Antibody

5739-100 each
EUR 405.6

PlGF-1 Antibody

5739-30T each
EUR 175.2

Mouse Placenta Growth Factor (PLGF) Protein

20-abx068553
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Placenta Growth Factor (PLGF) Protein

abx068553-20g 20 µg
EUR 562.5

Mouse Placenta Growth Factor (PLGF) Protein

abx068553-5g 5 µg
EUR 287.5

Placenta Growth Factor (PLGF) Polyclonal Antibody (Mouse)

4-PAA114Mu01
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Mouse Placenta Growth Factor (PLGF)

human anti-human PLGF mAb (AB1)

E4A09J01-AB1 50ug
EUR 255
Description: Available in various conjugation types.

human anti-human PLGF mAb (AB2)

E4A09J01-AB2 50ug
EUR 255
Description: Available in various conjugation types.

human anti-human PLGF mAb(AB7)

E4A09J01-AB7 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

human anti-human PLGF mAb(AB8)

E4A09J01-AB8 50ug
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Mouse PLGF(Placenta Growth Factor) ELISA Kit

ELK1242-48T 48T Ask for price
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse PLGF. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse PLGF. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse PLGF, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse PLGF in the samples is then determined by comparing the OD of the samples to the standard curve.

Mouse PLGF(Placenta Growth Factor) ELISA Kit

ELK1242-96T 96T Ask for price
Description: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Mouse PLGF. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Mouse PLGF. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Mouse PLGF, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Mouse PLGF in the samples is then determined by comparing the OD of the samples to the standard curve.

Mouse Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-Mu 96T
EUR 241
Description: serum, plasma, tissue homogenates or other biological fluids.

Mouse Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-Mu-48T 48T
EUR 380.4
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates or other biological fluids.

Mouse Placenta Growth Factor (PLGF) ELISA Kit

DLR-PLGF-Mu-96T 96T
EUR 477.6
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Placenta Growth Factor (PLGF) in samples from serum, plasma, tissue homogenates or other biological fluids.

Mouse placenta growth factor,PLGF Elisa kit

EK731467 96 Wells
EUR 0.79

Mouse Placenta growth factor, PlGF ELISA Kit

ELA-E0114m 96 Tests
EUR 1038

Mouse Placenta Growth Factor (PLGF) ELISA Kit

EKN47757-48T 48T
EUR 269.71

Mouse Placenta Growth Factor (PLGF) ELISA Kit

EKN47757-5x96T 5x96T
EUR 1830.18

Mouse Placenta Growth Factor (PLGF) ELISA Kit

EKN47757-96T 96T
EUR 385.3

Mouse Placenta Growth Factor (PLGF) ELISA Kit

EKL54888-5x96T 5x96T
EUR 1883.38

Mouse Placenta Growth Factor (PLGF) ELISA Kit

EKL54888-96T 96T
EUR 396.5

Mouse Placenta Growth Factor (PLGF) ELISA Kit

EKU06646-48T 48T
EUR 395.36

Mouse Placenta Growth Factor (PLGF) ELISA Kit

EKU06646-5x96T 5x96T
EUR 2682.8

Mouse Placenta Growth Factor (PLGF) ELISA Kit

EKU06646-96T 96T
EUR 564.8

Mouse placenta growth factor(PLGF)ELISA Kit  

GA-E0088MS-48T 48T
EUR 403.2

Mouse placenta growth factor(PLGF)ELISA Kit  

GA-E0088MS-96T 96T
EUR 640.8

Mouse Placenta Growth Factor (PLGF) ELISA Kit

DL-PLGF-Mu 96T
EUR 230
Description: serum, plasma, tissue homogenates or other biological fluids.

Mouse placenta growth factor, PLGF ELISA kit

CSB-E07401m-24T 1 plate of 24 wells
EUR 198
Description: Quantitativecompetitive ELISA kit for measuring Mouse placenta growth factor, PLGF in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Mouse placenta growth factor, PLGF ELISA kit

1-CSB-E07401m
  • Ask for price
  • Ask for price
  • Ask for price
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativecompetitive ELISA kit for measuring Mouse placenta growth factor, PLGF in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Mouse Placenta growth factor (PLGF) ELISA Kit

AE27811MO-48Tests 48 Tests
EUR 305
Description: Mouse (Mus musculus)

Mouse Placenta growth factor (PLGF) ELISA Kit

AE27811MO-96Tests 96 Tests
EUR 570
Description: Mouse (Mus musculus)

Mouse placenta growth factor,PLGF ELISA kit

CN-02373M1 96T
EUR 565.2

Mouse placenta growth factor,PLGF ELISA kit

CN-02373M2 48T
EUR 386.4

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Mu-48T 48T
EUR 235.7
Description: serum, plasma, tissue homogenates and other biological fluids.

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Mu-48Tests 48 Tests
EUR 354

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Mu-96T 96T
EUR 336.7
Description: serum, plasma, tissue homogenates and other biological fluids.

Mouse Placenta Growth Factor (PLGF) ELISA Kit

RD-PLGF-Mu-96Tests 96 Tests
EUR 480

Mouse Placenta growth factor (PLGF) ELISA Kit

RK06233 96T
EUR 280

Mouse placenta growth factor(PLGF)ELISA Kit

QY-E21188 96T
EUR 433.2

Mouse Placenta Growth Factor (PLGF)ELISA Kit

NSL1327m 96 Test
EUR 528
Importantly, our gamma band findings counsel an aberrant signal-to-noise ratio impairing cognition that happens with NMDAR hypofunction, doubtlessly tied to impaired task-dependent alteration in useful connectivity.

Leave a Reply

Your email address will not be published. Required fields are marked *